secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001104659-25-047871
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio starts Phase 3 Alzheimer's trial, reports Q1 net loss $0.32 per share, cash $22.2M
--------------------------------------------------------------------------------

- First participants entered pivotal Phase 3 AD trial on Feb 5, 2025; planning 760 participants, evaluating buntanetap.
- Cash and equivalents $22.2M as of Mar 31, 2025 (vs $10.6M a year ago).
- R&D expenses $5.0M in Q1 2025 vs $6.5M Q1 2024; G&A flat at $1.3M.
- Net loss per share $0.32 basic/diluted for Q1 2025 vs $0.10 basic and $0.72 diluted in Q1 2024.
- Appointed Andrew Walsh (VP Finance) as Principal Financial Officer; salary $264,000 + 25% target bonus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925047871/0001104659-25-047871-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465925047871/tm2514854d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-047871

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer